A citation-based method for searching scientific literature

Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
Times Cited: 57



J-F Yale, G Bakris, B Cariou, D Yue, E David-Neto, L Xi, K Figueroa, E Wajs, K Usiskin, G Meininger. Diabetes Obes Metab 2013
Times Cited: 354




List of shared articles



Times cited

SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
Konstantinos Imprialos, Charles Faselis, Chrysoula Boutari, Konstantinos Stavropoulos, Vasilios Athyros, Asterios Karagiannis, Michael Doumas. Curr Pharm Des 2017
10

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes.
Jessica W Skelley, Brooke S Carter, Megan Z Roberts. Vasc Health Risk Manag 2018
4

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.
Vishal Gupta, William Canovatchel, B N Lokesh, Ravi Santani, Nishant Garodia. Indian J Endocrinol Metab 2017
0


Response to Stavropoulos.
Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, C V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
0

Canagliflozin: metabolic, cardiovascular and renal protection.
Vivencio Barrios, Carlos Escobar. Future Cardiol 2021
1




SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Theodosios D Filippatos, Angelos Liontos, Ioanna Papakitsou, Moses S Elisaf. Postgrad Med 2019
24


An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
Joseph A Messana, Stanley S Schwartz, Raymond R Townsend. Vasc Health Risk Manag 2017
5